Oral Antibiotics for Second-Degree Burns
Oral antibiotics are NOT routinely indicated for uncomplicated second-degree burns; they should be reserved exclusively for burns with clinical signs of infection (purulent drainage, expanding erythema, fever, systemic toxicity) or specific high-risk scenarios. 1, 2
When Oral Antibiotics Are NOT Indicated
Uncomplicated Second-Degree Burns
- Do not prescribe prophylactic oral antibiotics for clean second-degree burns without signs of infection, as this promotes antimicrobial resistance without improving outcomes and is explicitly discouraged by burn management guidelines 1, 2, 3.
- Antimicrobial dressings (e.g., silver sulfadiazine, silver-impregnated dressings) provide adequate local infection control for most second-degree burns managed outpatient 1, 2.
- Superficial second-degree burns (2a) covering <10% total body surface area (TBSA) in adults or <5% TBSA in children can be managed with modern wound dressings alone without systemic antibiotics 2, 4.
Evidence Against Routine Prophylaxis
- Systematic review of 19 trials demonstrates that early postburn antibiotic prophylaxis shows no effectiveness for preventing toxic shock syndrome or burn wound infection in non-severe burn patients (Grade 1C evidence) 3.
- Prophylactic antibiotics may be useful only in severe burns requiring mechanical ventilation (Grade 2B evidence), which falls outside the scope of typical outpatient second-degree burns 3.
When Oral Antibiotics ARE Indicated
Clinical Signs of Infection
Prescribe oral antibiotics when any of the following are present:
- Purulent drainage or exudate from the burn wound 1, 2.
- Expanding erythema beyond the original burn margin, indicating cellulitis 1.
- Fever >38°C, tachycardia, or systemic inflammatory response suggesting invasive infection 1.
- Delayed healing or worsening wound appearance after initial improvement 2.
High-Risk Patient Populations Requiring Preemptive Therapy (3–5 Days)
The 2024 AHA/Red Cross First Aid Guidelines recommend preemptive antibiotics for burns in patients who are 1:
- Immunocompromised (HIV/AIDS, chemotherapy, chronic corticosteroids).
- Asplenic (functional or surgical).
- Advanced liver disease (cirrhosis).
- Preexisting or resultant edema of the affected area.
- Moderate to severe injuries, especially to the hand or face.
- Injuries penetrating periosteum or joint capsule.
First-Line Oral Antibiotic Regimens
For Typical Burn Wound Infections (Streptococci and MSSA Coverage)
- Cephalexin 500 mg orally every 6 hours for 5–7 days provides excellent coverage of beta-hemolytic streptococci and methicillin-sensitive Staphylococcus aureus, the predominant pathogens in burn wound infections 1.
- Dicloxacillin 250–500 mg orally every 6 hours for 5–7 days is an equally effective alternative 1.
- Amoxicillin-clavulanate 875/125 mg orally twice daily for 5–7 days offers broader coverage when polymicrobial infection (including anaerobes) is suspected 1, 5.
When MRSA Coverage Is Required
Add MRSA-active therapy only when specific risk factors are present:
- Purulent drainage or exudate from the burn wound 1.
- Known MRSA colonization or prior MRSA infection 1.
- Failure to respond to beta-lactam therapy after 48–72 hours 1.
- Systemic inflammatory response syndrome (fever, tachycardia, hypotension) 1.
MRSA-Active Oral Regimens:
- Clindamycin 300–450 mg orally every 6 hours for 5–7 days provides single-agent coverage for both streptococci and MRSA, but use only if local MRSA clindamycin resistance is <10% 1, 6.
- Trimethoprim-sulfamethoxazole 1–2 double-strength tablets twice daily PLUS cephalexin 500 mg every 6 hours ensures dual coverage when clindamycin resistance is high 1, 5.
- Doxycycline 100 mg orally twice daily PLUS a beta-lactam (cephalexin or amoxicillin) is an alternative combination, but avoid in children <8 years due to tooth discoloration risk 1, 5.
Treatment Duration and Monitoring
- Treat for 5–7 days if clinical improvement occurs (reduced warmth, tenderness, erythema; absence of fever); extend only if symptoms persist 1.
- Reassess within 24–48 hours to verify clinical response; treatment failure rates of ~21% have been reported with some oral regimens 1, 5.
- If no improvement after 48–72 hours, consider resistant organisms (MRSA), undrained abscess, deeper infection, or alternative diagnoses 1, 5.
Hospitalization Criteria (Requiring IV Antibiotics)
Admit patients with second-degree burns when any of the following are present:
- Systemic inflammatory response syndrome (fever, tachycardia, hypotension, altered mental status) 1, 7.
- Signs of deeper or necrotizing infection (severe pain out of proportion, skin anesthesia, rapid progression, "wooden-hard" tissue) 1.
- Burns >10% TBSA in adults or >5% TBSA in children 1, 2.
- Burns to special areas (hands, face, feet, genitals, major joints) 1, 2.
- Severe immunocompromise or neutropenia 1, 7.
Inpatient IV Regimens:
- Vancomycin 15–20 mg/kg IV every 8–12 hours (first-line for MRSA coverage, A-I evidence) 1, 7.
- Linezolid 600 mg IV twice daily (alternative MRSA agent, A-I evidence) 1, 7.
- Daptomycin 4 mg/kg IV once daily (alternative MRSA agent, A-I evidence) 1, 7.
- Clindamycin 600 mg IV every 8 hours (if local MRSA clindamycin resistance <10%, A-III evidence) 1, 6, 7.
- For severe infections with systemic toxicity or suspected necrotizing infection: Vancomycin or linezolid PLUS piperacillin-tazobactam 3.375–4.5 g IV every 6 hours 1, 7.
Adjunctive Measures (Essential for All Burns)
- Elevate the affected limb above heart level for at least 30 minutes three times daily to promote edema drainage 1, 5.
- Apply topical antimicrobial dressings (silver sulfadiazine, silver-impregnated dressings, or honey) to reduce bacterial colonization 1, 2.
- Verify tetanus prophylaxis is up-to-date; administer Tdap if no vaccination within 10 years 1.
- Avoid prolonged use of silver sulfadiazine on superficial burns, as it may delay healing 1.
Common Pitfalls to Avoid
- Do not prescribe prophylactic oral antibiotics for clean, uncomplicated second-degree burns; this promotes resistance without benefit 1, 2, 3.
- Do not use doxycycline or trimethoprim-sulfamethoxazole as monotherapy for burn wound infections, as they lack reliable activity against beta-hemolytic streptococci 1, 5.
- Do not add MRSA coverage reflexively without specific risk factors; MRSA is uncommon in typical burn wound infections 1, 5.
- Do not delay surgical consultation if signs of necrotizing infection, deep tissue involvement, or systemic toxicity develop 1, 7.
- Do not rely on antibiotics alone for infected burns; appropriate wound care, debridement, and source control are essential 7, 8.